<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196062</url>
  </required_header>
  <id_info>
    <org_study_id>CRE Ref. No. 2019.331</org_study_id>
    <nct_id>NCT04196062</nct_id>
  </id_info>
  <brief_title>EndoMaster EASE System for Treatment of Colorectal Lesions</brief_title>
  <acronym>MASTERCESD</acronym>
  <official_title>Prospective, Single Arm Study to Assess the Safety and Performance of the EndoMaster EASE System for the Treatment of Colorectal Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm study to assess the safety and performance of the
      EndoMaster EASE (Endoluminal Access Surgical Efficacy) System for the treatment of patients
      with colorectal neoplasms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single arm study to assess the safety and performance of robotically assisted
      ESD of superficial colorectal lesions, that otherwise cannot be optimally and radically
      removed by snare-based techniques
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, Single-Arm Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete (R0) resection</measure>
    <time_frame>30 days</time_frame>
    <description>rate of complete (R0) resection defined as en bloc, one-piece resection with histologically confirmed tumour-free lateral and vertical margins</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding during or after the procedure</measure>
    <time_frame>30 days</time_frame>
    <description>Bleeding as evidence by
Active bleeding during the robotic ESD procedure
Bleeding after ESD with clinical evidence of 1. Fresh hematemesis; 2. Passage of tarry stool with pulse &gt; 100 or systolic blood pressure &lt; 100; 3. Drop in hemoglobin level of &gt; 4 g/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perforation</measure>
    <time_frame>30 days</time_frame>
    <description>Perforation at the ESD site as assessed by endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunctive procedures to control bleeding</measure>
    <time_frame>1 day</time_frame>
    <description>Use of coagrapser / clips</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical sepsis with changes in inflammatory markers as evidence by
clinical symptoms of fever, pulse &gt; 100
radiological evidence of intraperitoneal collection
elevated WBC count of &gt; 10.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impairment of renal function</measure>
    <time_frame>30 days</time_frame>
    <description>renal failure as evidence of derangement of renal function with elevated creatinin level &gt; 100 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>Serous Adverse Events at preocedure and through discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of procedure</measure>
    <time_frame>1 day</time_frame>
    <description>OT time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operator assessment of device performance</measure>
    <time_frame>1 day</time_frame>
    <description>Operator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device deficiencies</measure>
    <time_frame>1 day</time_frame>
    <description>Device malfunction and Use errors during the ESD procedure as evidence by
cessation of the function of the EndoMASTER EASE system
need to use of the immediate cessation button for the EndoMASTER EASE system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of Hospital Stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology of resected specimen</measure>
    <time_frame>30 days</time_frame>
    <description>En bloc resection rate / R0 rate / positive vertical margin / positive lateral margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonoscopy followup</measure>
    <time_frame>6 months, 18 months to 3 years</time_frame>
    <description>Healing of operative site / presence of suspicious tissue for biopsy / presence of stricture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer status by cross-sectional imaging (MRI / CT)</measure>
    <time_frame>12 months and 3 years</time_frame>
    <description>local recurrence / recurrence at different site in colon / metastatic disease and location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>30 days</time_frame>
    <description>en bloc, one-piece excision of the neoplasm irrespective of histopathology, in the absence of device-related SAE through 30 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Colonic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Robotic ESD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of early colorectal neoplasia / lateral spreading tumors by ESD using EndoMASTER EASE robotic system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoMASTER EASE Robotic system for ESD</intervention_name>
    <description>EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery</description>
    <arm_group_label>Robotic ESD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤ 85;

          2. Suspected intramucosal neoplasm of the colon or rectum, including adenocarcinoma and
             tubular, tubulovillous, or villous adenomas.

        Exclusion Criteria:

          1. Informed consent not available;

          2. Carcinoma of colon or rectum with known involvement beyond the submucosa;

          3. Evidence of distant spread of colon cancer;

          4. Presence of another active malignancy;

          5. Pregnancy;

          6. Patients considered unfit for general anaesthesia;

          7. The endoscopic platform cannot reach the target site;

          8. Current participation in another clinical research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Chiu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Wai Yan Chiu, MD, FRCSEd</last_name>
    <phone>+85235053952</phone>
    <email>philipchiu@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Man Yee Yung</last_name>
    <phone>+85235052956</phone>
    <email>myyung@surgery.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Combined Endoscopy Center, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Chiu, MD</last_name>
      <phone>85226322627</phone>
      <email>philipchiu@surgery.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Man Yee Yung</last_name>
      <phone>+85235052956</phone>
      <email>myyung@surgery.cuhk.edu.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Philip WY Chiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Philip Wai Yan CHIU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Colonic ESD</keyword>
  <keyword>Robotic Endoscope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

